Relationship between Cardiovascular Disorder and Chronic Kidney Disease View PDF

*Ariel Pablo Lopez
Department Of Genetics, Universidad De Buenos Aires, Molecular Biology Laboratory, Universidad De Buenos Aires, Buenos Aires, Argentina

*Corresponding Author:
Ariel Pablo Lopez
Department Of Genetics, Universidad De Buenos Aires, Molecular Biology Laboratory, Universidad De Buenos Aires, Buenos Aires, Argentina
Email:aplopez@prensamedica.com.ar

Published on: 2022-10-17

Abstract

Cardiovascular and renal diseases are common and often co-occur, which significantly increases mortality, morbidity, complexity, and cost of treatment [1,2]. Comorbidities such as heart failure and renal failure exist. The term “cardio-renal syndrome” (CRS) refers to acute or chronic dysfunction of one organ that leads to the acute or chronic failure of another (Table 1) [3,4]. Moreover, renal failure in heart failure can result in reduced diuretic effect, increased blockage, and further loss of renal function, resulting in a vicious cycle. CRS was long assumed to be caused by renal hypoperfusion as a result of inadequate cardiac output and hyper-diuresis. Nevertheless, research has gradually revealed a link between Venous Thrombo Embolism (VTE) and CRS rather than insufficient cardiac output, which has been linked to CRS in right-sided heart problems in the latest generations. In contrast to a single cardiorenal illness, both Right heart failure (RHF) and CRS have complicated and interrelated pathogen physiological pathways that can impact various organs and systems. The most severe type of cardiorenal regulations is referred to be “CRS,” and treatment of obstructed symptoms is confined to impaired renal function. This physiological notion is distinct from the Acute Dialysis Quality Initiative [5] categorization systems, which specify main organ failure (cardiac or renal) and total duration (acute or chronic), with an extra category for clinical syndrome impacting both organs at the same time. Additionally, there are few quantifiable assessments of cardiac or renal function to characterize these subtypes; hence, their clinical use is mostly descriptive and cardiopulmonary. CRS occurs when people who have heart failure develop renal failure while being treated for heart failure. Renal failure in heart failure patients is complicated and generally multivariate in nature; nonetheless, the illness may be curable in certain people. Reducing angiotensin II levels with angiotensin-converting enzyme medications can help to avoid glomerular hyperfiltration and, in the long run, preserve kidney function.

Keywords

Cardiovascular Disorder, Chronic Kidney Disease, CKD, Cardio-renal Syndrome

Methods

Historically, “right ventricular failure” has been as the RV’s (right ventricular) inability to produce appropriate stroke volume, resulting in venous blood blockage, left ventricular hypo perfusion, and cardiac arrhythmia. Acute RHF can occur due to a rapid rise in RV afterload or a reduction in RV cardiac function (RV ischemia, myocardium, or postcardiomyopathy  shock). Upward flow (cardiac output) impairment, which leads to reduced urethral perfusion and neurosurgical activation, has long been regarded as a crucial event in CRS [6,7]. As a result, it is logical for RVs to participate in CRS as a critical source of proper perloading. Renal perfusion might persist until the cardiac index reached 1.5 L/min/m2 [8] which was sometimes described as “prenatal” in early CRS studies. Arterial hypo perfusion caused by decreased cardiac function and increased peripheral blood vessel resistance can activate the Renin-Angiotensin-Aldosterone System (RAAS), a sympathetic nervous system (SNS), and produce arginine oppressiveness, causing salt and water accumulation and progression of heart failure [9]. The National Registry of Acute Compensated Heart Failure (ADHERE) discovered the same rate of renal failure in patients with reduced and complete arterial pressure [10], indicating that regurgitation is unlikely to be the primary cause of the majority of CRS patients. Post-treatment Worsening Renal Function (WRF), on the other hand, is more prevalent in heart failure patients with intact ejection fraction than in those with considerably decreased ejection fraction [11]. It is critical to recognize that the occurrence of WRF in the context of reduced circulation differs markedly from the occurrence of WRF in the context of systemic venous embolism. In individuals with predominant RHF, systemic venous stenosis, as evaluated by inferior vena cava (IVC) diameter, is a predictor of Glomerular Filtration Rate (GFR), and a decrease in IVC size following treatment has been linked with improvement in GFR. A study of noninvasive and invasive venous overload measurements demonstrated a connection between elevated central venous pressure (CVP) and basic renal failure as well as WRF in acute coronary artery disease and high blood pressure. CVP was discovered to be an independent predictor of cardiac re-hospitalization [12] and mortality from any cause. Lastly, because of the intricate interaction between both the heart and kidney, venous congestion reduction markedly enhanced renal function in RV individuals with electrocardiography-verified bp, and the overall pathogenesis of CRS in RHF is complicated in numerous aspects. Systemic venous congestion can arise as a result of either solitary RV failure or biventricular dysfunction associated with RHF, which is frequently the actual reason for  many cardiovascular illnesses. The consequences of venous occlusion on numerous organs are crucial in the psychophysiology of CRS, since it increases the RAAS and SNS [13], produces diverticulitis owing to endothelial cell dysfunction, and causes venous, intestinal, and lymphatic congestion. Back pressure placed on the renal route by the systemically venous system can lead to a rise in renal venous pressure, which can have a direct influence on numerous renal functions [14] both locally and systemically. Systemic vascular occlusion is also caused by venous occlusion. Mechanical, metabolic, and immunological reactions all play a role in the progression of CRS. The consequences of vein thrombus and kidney failure on tissues other than the pulse and renal have been hypothesized and this was previously referred to as CRS. Originally, it was believed that increased renal venous pressure caused blockage of the renal pelvis in the non-expandable renal capsule leading to higher interstitial pressure impacting the whole capillary bed and tubules [15,16]. Renal tubular pressure has been demonstrated in experimental models to influence filtering fractions, baroreflex flow, and  innate vasculature reflex response  referring  to various inputs Transforming Growth Factor (TGF), RAAS, and SNS. Renal venous congestion caused by increased systemic pressure, often reflected by high CVP, leads to a lower kidney arteriovenous gradient and, ultimately, a reduced renal perfusion pressure. A progressive rise in kidney venous pressure, particularly during volume expansion, led to  a decrease in GFR in measures of the  filtration function. The myogenesis reaction is an auto-regulatory process of the renal system that is an innate capability of the glomerular capillaries in reaction to a rise in wall tension, resulting in smooth muscle cell contraction and activity of the myosin light chain kinase. In experimental experiments, changes in intra-abdominal pressures and kidney venous pressure have been demonstrated to impact serum enzyme activities and cortisol levels, yet this might not lead to substantial changes in hemodynamics including such heartbeat or systemic blood pressure [17]. Inflammation may be implicated in the pathogenesis of CRS, according to the study. Neurohormonal activation and vein obstruction, particularly localized blockage such as splenic obstruction and renal vein obstruction or venous blood crowding, may all contribute to the generation of inflammatory cells as a function of heart failure. Elevated expression of cytokines such as carcinoma cells factor-tumor  necrosis factor-α, interleukin-6,  and interleukin-1 have been linked to poor health outcomes in heart problems. End organ damage sets off a vicious cycle of increasing congestion and inflammatory activity.

Conclusion

CRS types 1 and 2 are intricate two-way linkages between both the heart and the kidneys that indicate kidney problems induced by both acute and long-term heart failure, respectively. Elevated expression of cytokines including tumor  necrosis factor-α, interleukin-6, and interleukin-1 have been linked to poor health outcomes in heart failure [18]. End organ damage sets off a vicious cycle of increasing permeability and inflammatory activation issues. Current research has discovered a substantial link between venous thrombosis and renal failure in heart failure, showing that the right heart plays an important role. The primary objective is to avoid Temporoparietal Junction Functional (TPJ). This necessitates an understanding of CRS physiologists, which includes several interfaces and is not confined to the heart and kidneys. This is due to the pressure impact of venous blockage, inflammatory responses, neurohormonal activation, and splanchnic organs. Reduced blockage remains the most essential therapy for specific rates and CRS, although it is clinically challenging. Reduced diuretic effectiveness and resistance may result in prosecution. On the other hand, the precise diuretic strategy for  CRS or diuretic resistance is yet unclear, and further random studies are required [19]. Therefore, clinical evaluation of intracellular hydration balance is necessary to keep the equilibrium of hypervolemia and dehydration.

References

  1. Heywood JT (2005) The cardiorenal syndrome: lessons from the ADHERE database and treatment options. Heart Fail Rev 9: 195-201. https://doi.org/10.1007/s10741-005- 6129-4
  2. Forman DE, Butler J, Wang Y, Abraham WT, O’Connor CM, et al. (2004) Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 43: 61-67. https://doi.org/10.1016/j. jacc.2003.07.031
  3. Schrier RW, Abraham WT (1999) Hormones and hemodynamics in heart failure. N Eng J Med 341: 577-585. https://doi.org/10.1056/NEJM199908193410806
  4. Ljungman S, Laragh JH, Cody RJ (1990) Role of the kidney in congestive heart failure: relationship of cardiac index to kidney function. Drugs 39: 10-21. https://doi. org/10.2165/00003495-199000394-00004
  5. Adams Jr KF, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, et al. (2005). Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149: 209-216. https://doi.org/10.1016/j.ahj.2004.08.005
  6. Uthoff H, Thalhammer C, Potocki M, Reichlin T, Noveanu M, et al. (2010) Central venous pressure at emergency room presentation predicts cardiac rehospitalization in patients with decompensated heart failure. Eur J Heart Fail 12: 469-476. https://doi. org/10.1093/eurjhf/hfq024
  7. Kastner PR, Hall JE, Guyton AC (1982) Renal hemodynamic responses to increased renal venous pressure: role of angiotensin II. Am J Physiol 243: F260-F264. https://doi. org/10.1152/ajprenal.1982.243.3.F260
  8. Schrier RW (2008) Blood urea nitrogen and serum creatinine: not married in heart failure. Circ Heart Fail 1: 2-5. https://doi.org/10.1161/CIRCHEARTFAILURE.108.770834
  9. Komuro K, Seo Y, Yamamoto M, Sai S, Ishizu T, et al. (2018) Assessment of renal perfusion impairment in a rat model of acute renal congestion using contrast-enhanced ultrasonography. Heart Vessels 33: 434-440. https://doi.org/10.1007/s00380-017-1063-7 
  10. Ruggenenti P, Remuzzi G (2011) Worsening kidney function in decompensated heart failure: treat the heart, don’t mind the kidney. Eur Heart J 32: 2476-2478. https://doi.org/10.1093/eurheartj/ehr242 
  11. 11. Ross EA (2012) Congestive renal failure: the pathophysiology and treatment of renal venous hypertension. J Card Fail 18: 930-938. https://doi.org/10.1016/j.cardfail.2012.10.010
  12. Fiksen-Olsen MJ, Strick DM, Hawley H, Romero JC (1992) Renal effects of angiotensin II inhibition during increases in renal venous pressure. Hypertension 19: II137. https://doi.org/10.1161/01.hyp.19.2_suppl.ii137
  13. Braam B, Cupples WA, Joles JA, Gaillard C (2012) Systemic arterial and venous determinants of renal hemodynamics in congestive heart failure. Heart Fail Rev 17: 161-175. https://doi.org/10.1007/s10741-011-9246-2
  14. Schirmer HK, Marshall RE, Jackson MP (1968) The effect of altered renal venous pressure on urine flow and cortical metabolism. J Urol 100: 205-208. https://doi.org/10.1016/s0022-5347(17)62506-0 
  15. Boberg U, Persson AE (1985) Tubuloglomerular feedback during elevated renal venous pressure. Am J Physiol 249: F524-F531. https://doi.org/10.1152/ajprenal.1985.249.4.F524 
  16. Burnett Jr JC, Knox FG (1980) Renal interstitial pressure and sodium excretion during renal vein constriction. Am J Physiol 238: F279-F282. https://doi.org/10.1152/ ajprenal.1980.238.4.F279
  17. Dilley JR, Corradi A, Arendshorst WJ (1983) Glomerular ultrafiltration dynamics during increased renal venous pressure. Am J Physiol 244: F650-F658. https://doi. org/10.1152/ajprenal.1983.244.6.F650
  18. Haddy FJ, Scott J, Armstrong E (1956) Effect of elevation of intraluminal pressure on renal vascular resistance. Circ Res 4: 659-663. https://doi.org/10.1161/01.res.4.6.659
  19. Kishimoto T, Maekawa M, Abe Y, Yamamoto K (1973) Intrarenal distribution of blood flow and renin release during renal venous pressure elevation. Kidney Int 4: 259-266. https://doi.org/10.1038/ki.1973.11 

Copyright © 2024 Scholars Literature. All rights reserved.

scroll up